サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1138396

3Dプリント医薬品の世界市場-2022-2029

Global 3D Printed Drugs Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
3Dプリント医薬品の世界市場-2022-2029
出版日: 2022年10月18日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

世界の3Dプリント医薬品市場の成長は、世界の医療障害の増加、安価な医薬品や錠剤の需要の高まり、医療産業における3Dプリントの適応性の高まりなど、いくつかの要因によって推進されています。瞬時溶解性など、3Dプリント医薬品の利点に対する認識が高まっているためです。3Dプリントされた医薬品は、非常に飲み込みやすくなっています。これらの薬剤は、すべての患者の要件に従ってカスタマイズすることができ、バッチ生産された薬剤よりも優れた方法で支援するため、予測期間中に需要が増加すると予想されます。

3Dプリンティング技術の進歩や投資の増加が、予測期間中の原動力になると予想されます。

2020年10月、中国の四川大学と厦門大学の研究者は、神経治癒薬を送達できる3Dプリント自己粘着包帯を開発しました。この研究チームが作製したガーゼは、クリックで作動する2枚のハイドロゲル層と、再生薬を装填できる内側部分からなります。神経の損傷部位に巻き付けると、末梢神経系（PNS）のグリア細胞の成長を促すように薬剤が放出されます。将来的には、3Dプリンターで作られたこの新しいドレッシングが、神経切除術などの神経修復手術に広く用いられている医師を支援できるようになると、研究者たちは考えています。さらに、高効率の3Dプリント医薬品を開発するための研究活動を強化するための投資の高まりは、予測期間中の市場の成長を後押しすると予想されます。例えば、2020年12月、中国の3Dプリント技術スタートアップであるTriastek社は、3Dプリント医薬品の研究開発を加速させるため、シリーズA資金として1500万米ドルを調達しました。資金管理会社のDalton Ventureがこの資金調達ラウンドを主導し、その他の共同投資家にはShangahi Tofflon Science, Technology会長のZheng Xiaodong、Yunqi Partnersが含まれています。Triastekは、中国と米国での登録申請と並行して、3Dプリント医薬品の研究開発と大規模な生産ラインの建設に資金を使用する予定です。以上のことから、予測期間において、市場の牽引役となることが期待されます。

抑制要因

しかし、3dプリント医薬品の副作用や政府規制の欠如が市場成長の妨げになると予想されます。また、いくつかの不祥事やオンラインに保存されたデータのハッキングにより、患者はますます医療情報の開示に消極的になる可能性があります。さらに、3Dプリント医薬品を準備するためには、患者、その投与量、病歴の3D設計図を作成する必要があるため、設計図の誤表示や間違った説明の入力も市場の大きな課題となっています。

産業分析

3Dプリント医薬品市場は、アンメットニーズ、価格分析、サプライチェーン分析、規制分析など、様々な産業要因に基づく市場の詳細な分析を提供しています。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

  • 薬物別市場内訳
  • 技術別市場内訳
  • エンドユーザー別市場内訳
  • 地域別市場内訳

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 医療業界における3Dプリンティングの利用率上昇
      • 個別化医薬品の採用が増加
    • 抑制要因
      • 3Dプリンターで製造された薬剤の副作用
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • 規制分析
  • プライシング分析
  • サプライチェーン分析
  • 製品イノベーション
  • アンメットニーズ

第6章 薬物別

  • スプリタム
  • その他

第7章 技術別

    • インクジェットプリンティング
    • 溶融積層造形法（FDM）
    • ステレオリソグラフィー（SLA）
    • その他

第8章 エンドユーザー別

    • 病院
    • クリニック
    • 研究機関
    • その他

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第10章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A（合併・買収）分析

第11章 企業プロファイル

  • Aprecia Pharmaceuticals
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • GlaxoSmithKline Plc.
  • Hewlett Packard Caribe, BV, LLC
  • FabRx Ltd.（*LIST NOT EXHAUSTIVE）

第12章 DataM

目次
Product Code: DMPH1495

Market Overview

3D Printed Drugs Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 8.10% during the forecast period (2022-2029)

3D printed drugs are drugs manufactured by solidifying layers of materials to form a definite 3D structure. The adaptability of 3D printing is also applied for the precise and unique dosing of medicines to present more efficient drug administration. 3D printing is expected to be an efficient method to enhance the application of several controlled drug release mechanisms during the forecast period.

Market Dynamics

The global 3D printed drugs market growth is driven by several factors such as rising healthcare disorders globally and rising demand for cheaper drugs or pills, and increasing adaptability of 3D printing in the medical industries. With rising awareness of the advantages of 3D printed drugs, such as their instantaneous solubility. 3D printed drugs are extremely easy to swallow. As these drugs can be customized according to the requirement of every patient, assisting way better than batch-produced drugs, the demand is expected to grow over the forecast period.

Growing advancements in 3D Printing Technology and rising investments are expected to drive in the forecast period.

In October 2020, researchers from China's Sichuan University and Xiamen University developed 3D printed self-adhesive bandages capable of delivering nerve-healing drugs. The team's fabricated gauze comprises two click-activated hydrogel layers and an inner section that can be loaded with regenerative medicine. Once wrapped around the site of an injured nerve, the device releases the medication in a way that encourages the growth of glial cells in the Peripheral Nervous System (PNS). In the future, the scientists believe that their novel 3D printed dressing design could assist doctors carrying out widely-used nerve repair operations such as neurorrhaphy. Moreover, the rising investments to increase the research activities for developing highly efficient 3D printed drugs are expected to boost the market's growth during the forecast period. For instance, in December 2020, Triastek, a Chinese 3D printing technology startup, raised $15 million in Series A funding to accelerate the research and development of its 3D-printed drugs. The fund management company Dalton Venture led the funding round, while other co-investors included Shangahi Tofflon Science, Technology Chairman Zheng Xiaodong, and Yunqi Partners. Triastek will use the funds for the research and development of its 3D printed medicines alongside registration applications in China and the US and in constructing a large-scale production line. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

However, the adverse effects of 3d printed drugs' lack of government regulations are expected to hinder the market's growth. Also, several scandals and hacking of data stored online could make patients increasingly reluctant to disclose their medical information. In addition, mislabelling blueprints and inputting wrong descriptions is also a big challenge for the market as a 3D blueprint must be made of the patient, their dosage, and medical history to prepare a 3D printed drug.

Industry Analysis

The 3D printed drugs market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis

Fused Deposition Modelling (FDM) segment is expected to hold the largest market share in the 3D printed drugs market.

The fused deposition modelling (FDM) segment accounted for the largest market share in 2021. The segment benefits because FDM is a production method used for fabrication, production applications, and mechanical system modeling. The technique produces a tissue scaffold using a layer-by-layer thermoplastic polymer by the melt extrusion method. It is also known as material extrusion and is currently the most popular AM technology on the market. It fabricates durable components made of high-strength thermoplastics such as ULTEM, polycarbonate, polyphenylsulfone, polylactic acid, and acrylonitrile butadiene styrene. The FDM technique is one of the most widespread in drug 3D printing. Filaments loaded with medicines can be used for the manufacture of the pills. Fused Deposition Modeling (FDM) can make combinations of multiple drugs (polyps) and sustained or delayed-release tablets. The unique design of the FDM printer allows it to make gantry rails longer and expand the build area's size. This mechanism allows the designer to scale any print as wishes easily. The cost-to-size ratio is an added advantage for the user of the FDM printer. However, the FDM printer might be the best option for personal use, but when it comes to mass production, it is advised against using it.

Moreover, FDM printers are compatible with a wide variety of thermoplastic polymers like PLA and ABS and Polycarbonates such as PET, PS, ASA, PVA, Nylon, and even composite filaments based on metal, stone, wood, and more. These composites often offer interesting mechanical properties such as being conductive, bio-compatible, or heat resistant. These materials vary in price, with 1kg of PLA filament retailing at around $30/£20. FabRx's fused deposition modeling (FDM) 3D printers melt a mixture of drugs and excipients through a nozzle onto a build plate to construct a dosage form layer-by-layer. FabRx manufactures its filaments, comprised of pharmaceutical-grade materials, which can be drug-loaded to create sustained or delayed-release tablets and multi-drug combinations (polypills). FDM 3D printers range in price greatly. The cheapest, self-assemble RepRap types start at €300. This price costs €2,500 for medium-range models and nearly €10,000 for professional-level machines. The main players in this market include the original manufacturer Stratasys, brands like MakerBot (acquired by Stratasys in 2013), Ultimaker and Prusa. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North American region is expected to hold the largest market share in the global 3D printed drugs market.

North America has the largest share in the global 3D printed drugs market. The US is the only country that has approved the first 3D drug called Spritam (levetiracetam). The first 3D-printed drug to receive approval from the US Food and Drug Administration (FDA) is now being shipped to pharmacies. The company is also working on at least three other 3D-printed drugs it expects to bring to market eventually. Levetiracetam, the generic name for Spritam, has been available for treating seizures for 15 years. But the new brand Spritam is the first to use the proprietary 3D-printing process to create a more dissolvable pill. The surge in demand for instantaneous soluble drugs that can disperse easily in the mouth is the major factor driving the country's market growth.

Additionally, many state of the art universities collaborate with 3D drug manufacturing companies to research and develop new pharmaceuticals. For instance, in 2020, Aprecia Pharmaceuticals LLC partnered with Purdue University's College of Pharmacy to advance the technology and science of 3D pharmaceutical printing. Through this partnership, the companies will focus on developing future 3D-printed pharmaceutical equipment and medications. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the 3D printed drugs market are Aprecia Pharmaceuticals, GlaxoSmithKline Plc., Hewlett Packard Caribe, BV, LLC, FabRx Ltd.

GlaxoSmithKline PLC:

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat acute and chronic diseases. The Vaccines business provides vaccines for people of all ages, from babies and adolescents to adults and older people. It has a portfolio of medicines for respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty Products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, and older people and travel vaccines

Product Portfolio:

Ropinirole: The piezo-activated inkjetting to 3D print ropinirole hydrochloride. The tablets produced consist of a cross-linked poly(ethylene glycol diacrylate) (PEGDA) hydrogel matrix containing the drug, photoinitiated in a low oxygen environment using an aqueous solution of Irgacure 2959.

The global 3D printed drugs market report would provide an access to an approx. 45+market data table, 40+figures

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Drug
  • 3.2. Market snippet by Technology
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising usage of 3D printing in the medical industries
      • 4.1.1.2. Increasing adoption of personalized drugs
    • 4.1.2. Restraints
      • 4.1.2.1. Adverse effects of 3D printed drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Pricing Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Product Innovations
  • 5.6. Unmet Needs

6. By Drug

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Segment
  • 6.3. Market Attractiveness Index, By Drug Segment
    • 6.3.1. Spritam *
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 6.3.2. Others

7. By Technology

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Segment
  • 7.3. Market Attractiveness Index, By Technology Segment
    • 7.3.1.
      • 7.3.1.1. Inkjet printing*
      • 7.3.1.1.1. Introduction
      • 7.3.1.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
      • 7.3.1.2. Fused deposition modelling (FDM)
      • 7.3.1.3. Stereolithography (SLA)
      • 7.3.1.4. Others

8. By End-User

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
  • 8.3. Market Attractiveness Index, By End-User Segment
    • 8.3.1.
      • 8.3.1.1. Hospitals*
      • 8.3.1.1.1. Introduction
      • 8.3.1.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
      • 8.3.1.2. Clinics
      • 8.3.1.3. Research Laboratories
      • 8.3.1.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Aprecia Pharmaceuticals*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. GlaxoSmithKline Plc.
  • 11.3. Hewlett Packard Caribe, BV, LLC
  • 11.4. FabRx Ltd. (*LIST NOT EXHAUSTIVE)

12. DataM Intelligence

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us